Wave Life Sciences Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WVE research report →
About the company
Wave Life Sciences Ltd. , a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
- CEO
- Paul Bolno
- IPO
- 2015
- Employees
- 317
- HQ
- Singapore, MA, SG
Price Chart
- Market Cap
- $1.20B
- P/E
- -5.91
- P/S
- 16.78
- P/B
- 2.45
- EV/EBITDA
- -3.87
- Div Yield
- 0.00%
- Gross Margin
- 93.79%
- Op Margin
- -274.21%
- Net Margin
- -255.70%
- ROE
- -56.41%
- ROIC
- -36.32%
- Revenue
- $42.73M · -60.55%
- Net Income
- $-204,378,000 · -110.68%
- EPS
- $-1.21 · -72.86%
- Op Income
- $-215,383,000
- FCF YoY
- -23.38%
- 52W High
- $21.73
- 52W Low
- $5.02
- 50D MA
- $6.43
- 200D MA
- $9.72
- Beta
- -1.29
- Avg Volume
- 3.80M
Get TickerSpark's AI analysis on WVE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 9, 26 | Wright Christopher I | other | 0 |
| Apr 9, 26 | Wright Christopher I | other | 300,000 |
| Apr 9, 26 | Wright Christopher I | other | 273,750 |
| Apr 9, 26 | Ingelsson Erik | other | 0 |
| Apr 9, 26 | Ingelsson Erik | other | 350,000 |
| Apr 9, 26 | Ingelsson Erik | other | 200,000 |
| Apr 9, 26 | Ingelsson Erik | other | 273,750 |
| Mar 30, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 971,091 |
| Mar 27, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 2,495,623 |
| Mar 26, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 351,224 |
Our WVE coverage
Recent articles, reports, and earnings notes.
No research on WVE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WVE report →Similar companies
Peers in the same neighborhood.